PD-1 Blockade in Mismatch Repair-Deficient Rectal Cancer. Reply.

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

Who cites it

11 citing papers in PubMed, 1 synthesis or guideline pooled it.

1. Executive summary of American Radium Society Appropriate Use Criteria for the treatment of locoregionally recurrent rectal cancer.Cancer · 2026
   Pooled it
2. Neoadjuvant intratumoral influenza vaccine treatment in patients with proficient mismatch repair colorectal cancer leads to increased tumor infiltration of CD8+ T cells and upregulation of PD-L1: a phase 1/2 clinical trial.Journal for immunotherapy of cancer · 2023
   Trial
3. Suppression of transcription-replication conflicts by sequence-coordinated actions of TRDMT1 and MutLα.Nature communications · 2026
   Article
4. Innate immunity in tumour immunoediting and immunosurveillance.The EMBO journal · 2026
   Review
5. Interview with the World Class Authorities Frontiers of Cancer Research: An exclusive interview with Professor Luis Diaz.Annals of gastroenterological surgery · 2025
   Article
6. Integration of lipidomics with targeted, single cell, and spatial transcriptomics defines an unresolved pro-inflammatory state in colon cancer.Gut · 2025
   Article
7. Stage IV Rectal Cancer and Timing of Surgical Approach.Clinics in colon and rectal surgery · 2024
   Review
8. Sensitive, non-immunogenicCell stress · 2023
   Article
9. Evaluating the efficacy and safety of neoadjuvant pembrolizumab in patients with stage I-III MMR-deficient colon cancer: a national, multicentre, prospective, single-arm, phase II study protocol.BMJ open · 2023
   Article
10. Personalizing neoadjuvant immune-checkpoint inhibition in patients with melanoma.Nature reviews. Clinical oncology · 2023
    Review
11. A Phase I-II multicenter trial with Avelumab plus autologous dendritic cell vaccine in pre-treated mismatch repair-proficient (MSS) metastatic colorectal cancer patients; GEMCAD 1602 study.Cancer immunology, immunotherapy : CII · 2023
    Article

Corrections and comments

• Comment on
  PD-1 Blockade in Mismatch Repair-Deficient Rectal Cancer.2022
• Comment on
  PD-1 Blockade in Mismatch Repair-Deficient Rectal Cancer.2022

Authors and funding

2 authors.

Funding

No grant is acknowledged in the PubMed record.

Abstract

PubMed holds no abstract for this paper.

Indexed as